BioCentury | Jan 14, 2013
Clinical News

UMK-121: Phase I start

...to the UMK-121 technology covering the mobilization of bone marrow stem cells from the not-for-profit Cohen McNiece Foundation Inc....
BioCentury | Mar 5, 2012
Clinical News

UMK-121: Phase I started

...to the UMK-121 technology covering the mobilization of bone marrow stem cells from the not-for-profit Cohen McNiece Foundation Inc....
BioCentury | Dec 5, 2011
Company News

Proteonomix Inc., University of Miami deal

...to the UMK-121 technology covering the mobilization of bone marrow stem cells from the not-for-profit Cohen McNiece Foundation Inc....
BioCentury | Mar 21, 2011
Company News

Proteonomix, Cohen McNiece Foundation Inc. deal

...royalties. Further terms were not disclosed (see BioCentury, March 14). Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Cohen McNiece Foundation Inc....
Items per page:
1 - 4 of 4
BioCentury | Jan 14, 2013
Clinical News

UMK-121: Phase I start

...to the UMK-121 technology covering the mobilization of bone marrow stem cells from the not-for-profit Cohen McNiece Foundation Inc....
BioCentury | Mar 5, 2012
Clinical News

UMK-121: Phase I started

...to the UMK-121 technology covering the mobilization of bone marrow stem cells from the not-for-profit Cohen McNiece Foundation Inc....
BioCentury | Dec 5, 2011
Company News

Proteonomix Inc., University of Miami deal

...to the UMK-121 technology covering the mobilization of bone marrow stem cells from the not-for-profit Cohen McNiece Foundation Inc....
BioCentury | Mar 21, 2011
Company News

Proteonomix, Cohen McNiece Foundation Inc. deal

...royalties. Further terms were not disclosed (see BioCentury, March 14). Proteonomix Inc. (OTCBB:PROT), Mountainside, N.J. Cohen McNiece Foundation Inc....
Items per page:
1 - 4 of 4